| SC 13D/A | 2024-04-10 | TAKEDA PHARMACEUTICAL CO LTD | Phathom Pharmaceuticals, Inc. | 2,790,480 | 4.8% | EDGAR |
| SC 13D/A | 2024-04-01 | TAKEDA PHARMACEUTICAL CO LTD | Phathom Pharmaceuticals, Inc. | 3,153,217 | 5.4% | EDGAR |
| SC 13G/A | 2024-02-12 | Carlyle Group Inc. | Phathom Pharmaceuticals, Inc. | 3,496,808 | 6.1% | EDGAR |
| SC 13G/A | 2024-02-09 | Invesco Ltd. | Phathom Pharmaceuticals, Inc. | 3,167,653 | 5.5% | EDGAR |
| SC 13G/A | 2024-01-26 | Medicxi Growth I LP | Phathom Pharmaceuticals, Inc. | 3,673,602 | 6.4% | EDGAR |
| SC 13D/A | 2024-01-25 | TAKEDA PHARMACEUTICAL CO LTD | Phathom Pharmaceuticals, Inc. | 3,755,583 | 6.6% | EDGAR |
| SC 13D/A | 2023-05-26 | Frazier Life Sciences Public Fund, L.P. | Phathom Pharmaceuticals, Inc. | 5,827,415 | 10.7% | EDGAR |
| SC 13D/A | 2023-05-05 | Frazier Life Sciences Public Fund, L.P. | Phathom Pharmaceuticals, Inc. | 5,827,415 | 13.4% | EDGAR |
| SC 13G | 2023-03-09 | Carlyle Group Inc. | Phathom Pharmaceuticals, Inc. | 2,935,106 | 6.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Avidity Partners Management LP | Phathom Pharmaceuticals, Inc. | 1,900,000 | 4.6% | EDGAR |
| SC 13G/A | 2023-02-10 | Flynn James E | Phathom Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Phathom Pharmaceuticals, Inc. | 1,076,605 | 2.6% | EDGAR |
| SC 13G/A | 2023-02-09 | JANUS HENDERSON GROUP PLC | Phathom Pharmaceuticals, Inc. | 2,952 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-02 | Invesco Ltd. | Phathom Pharmaceuticals, Inc. | 2,207,649 | 5.3% | EDGAR |
| SC 13G/A | 2023-01-31 | Medicxi Growth I LP | Phathom Pharmaceuticals, Inc. | 2,426,630 | 5.8% | EDGAR |
| SC 13D/A | 2022-09-26 | Frazier Life Sciences IX, L.P. | Phathom Pharmaceuticals, Inc. | 5,827,415 | 14.9% | EDGAR |
| SC 13G | 2022-09-23 | Flynn James E | Phathom Pharmaceuticals, Inc. | 2,414,897 | 5.8% | EDGAR |
| SC 13D/A | 2022-08-11 | Frazier Life Sciences IX, L.P. | Phathom Pharmaceuticals, Inc. | 5,827,415 | 14.9% | EDGAR |
| SC 13G/A | 2022-05-16 | RA CAPITAL MANAGEMENT, L.P. | Phathom Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | RA CAPITAL MANAGEMENT, L.P. | Phathom Pharmaceuticals, Inc. | 3,115,008 | 9.9% | EDGAR |